Hindustan Unilever Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/lsrnfy7k7hi0zn9t50kjrwpq.pdf

Key Takeaways


Demand & Macro Environment

Rohit Jawa: "Most likely, the worst is past us and from here onwards we do see gradual recovery in rural consumption."

Portfolio Performance: The Two-Speed Story

Premium & performing

Mass & challenged

Rohit Jawa: "We are quite certain it's not quality. In fact, quality is better. It is the few grammage short of the benchmark in ₹10 price points in 2 very specific price-sensitive regions, where we sell a lot."

Beauty & Personal Care Restructuring


Distribution & Channel Shifts

Rohit Jawa: "The industry is all focused on growth right now. And we haven't quite settled to any equilibrium, where we can have a very informed discussion on margins."

Margins & Reinvestment

Ritesh Tiwari: "Medium to long term, we have always called out that our stated ambition is to do modest margin improvement. But if I just bring it back now for next some quarters, this is a level that we want to maintain the margin."

Competitive Position & Market Shares

Rohit Jawa: "We have held the massive share gains that we made during the inflation period which is not typical of other cycles we've had, where we've actually donated back the shares. In this case, we've held and we lost a little bit marginal share and 10, 20 basis points, but we're still holding pretty much by largely holding share."

Strategic Initiatives & Portfolio Moves

Rohit Jawa: "We will, in all full transparency, be more coherent around the food business, our packaged food and drink business in a few more months than we have made up our mind and where we actually feel we have the right to win, and how we would like to grow that business."

Guidance & Commitments

CommitmentSpecificsTimeline
Soap volume recoveryCorrective pricing in market; early signals visibleNext quarter or two
Pricing trajectoryLow single-digit decline near term; plateau midterm; positive low single digitsSecond half FY25
EBITDA marginMaintain at ~23.4%Near term (next few quarters)
EBITDA margin ambitionModest improvement toward 24%+ band, contingent on volume/pricing recovery and operating leverageMedium to long term
MAT business winning metricReturn above 60%Second half of calendar 2024
GSK distribution drag60 bps EBITDA margin impactNext 4 quarters
Beauty & Wellbeing financial disclosureDetailed segment reporting to beginJune quarter FY25
Ice cream separation (global)Unilever to complete separationSecond half of calendar 2025
Ice cream separation (India)Board and management to work through implications; no conclusion yetUndated
Food business strategyCoherent strategy to be communicated"A few more months"

Key Metrics

MetricQ4 FY24
Underlying sales growth1%, pricing marginally negative
Underlying volume growth2%
EBITDA margin23.4%, declined 30 bps YoY
Gross margin51.3%, improved 350 bps YoY
PAT (bei) growth-3% YoY
PAT growth-6% YoY
Home Care USG1%, mid-single-digit volume growth
Beauty & Personal Care USG-2%, volumes flat
Beauty & Wellbeing USGmid-single-digit, volume-driven
Personal Care USG-10%
Foods & Refreshment USGmid-single-digit, flat volumes
A&P investment10.8% of sales, up 200 bps YoY; absolute A&P up almost ₹300 cr
Full-year EBITDA margin23.8%, up 40 bps YoY
Full-year USG3%, underlying volume growth 2%
Full-year PAT (bei) growth4%
Full-year EPS growth2%
Total dividend for FY24₹42 per share, 8% YoY increase; final dividend ₹24, interim ₹18
MAT business winning metricbelow 60%, dipped from lapping high base
Corporate market share vs 2021improved almost 200 bps, marginal dip in recency
Brands over ₹1,000 cr turnover19 brands, over 80% of turnover; Clinic Plus now ₹2,000 cr
Market making & premiumization portfolio>25% of business, double-digit growth in FY24
Beauty big bets portfolio₹2,000 cr, double-digit growth, c.50% growth in e-commerce
Home Care liquids businesswell in excess of ₹3,500 cr
Shikhar e-B2B stores onboarded0.13 crore
Effective coverage vs FY201.2x
Assortment vs FY201.25x
On-shelf availability improvement (modern trade)200 bps
Online availability improvement (e-commerce)500 bps
GSK consignment termination EBITDA impact60 bps starting this quarter; combined with royalty increase, 90 bps impact
Effective tax rate (full year)26%, after prior-period tax adjustment